Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
EMP-012 by Empirico for Inflammation: Likelihood of Approval
EMP-012 is under clinical development by Empirico and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs...
Data Insights
EMP-012 by Empirico for Unspecified Immunological Disorders: Likelihood of Approval
EMP-012 is under clinical development by Empirico and currently in Phase I for Unspecified Immunological Disorders. According to GlobalData, Phase...